Overview
JUNSHI BIO (1877)
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The...
- Open
- 15.010
- High
- 15.100
- Low
- 14.000
- Prev. Close
- 14.950
- Volume
- 2.64M
- Turnover
- 37.55M
- Avg Price
- 14.248
- Bid/Ask Ratio
- 15.79%
- Amplitude
- 7.36%
- 52wk High
- 30.800
- Volume Ratio
- 0.60
- Turnover Ratio
- 1.01%
- 52wk Low
- 14.000
- HK Mkt Cap
- 3.69B
- Market CapHKD
- 14.54B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.448
- EPSDynamic
- -0.226
- EPSStatic
- --
- BVPS
- 6.62
- P/B
- 2.14
- HK Shares
- 260.30M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 1.03B
- Min lot size
- 200
- Currency
- HKD
JUNSHI BIO Analyst Rating
View moreForecast & Rating
Nov 3, 2026- Strong buy75.00%
- Buy0.00%
- Hold25.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 3
- Buy
- 0
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Junshi Biosciences fell 4.48% to HK$14.28 in a spike-and-fade session: it opened at HK$15.01, tagged HK$15.10 in the morning, then slid to HK$14.00 before closing near the low on HK$37.4 million turnover, extending the weak tone after the stock set a fresh 52-week low of HK$14.00 in the prior session. Fundamentals cut against the tape: Q3 2026 revenue rose 37.21% year on year to HK$956.1 million and operating income jumped 230.21% to HK$172.3 million, yet the quarter still posted a HK$199.9 million net loss with EPS of -HK$0.2445, down 23.83%, versus Q2's HK$48.8 million net profit; the regular approval of toripalimab in urothelial cancer and first dosing of JS207 plus JS007 in a Phase 3 liver cancer trial did not lift the shares. At HK$14.28 the price sits below the MA20 of HK$15.81 and MA60 of HK$17.20, down 35.91% year to date and 53.64% from the HK$30.80 52-week high, just 2% above the low, with PB at 2.16x. Though CICC carries a Buy rating and revenue has grown above 37% for two straight quarters.
- Nov, 13
Junshi Biosciences fell 5.02% to HK$14.95 on 13 Nov in a spike-and-fade session: it printed HK$15.65 at 09:36 BJ before sliding to HK$14.95 by 15:50 on 1.23 million shares. Phase 3 lung-cancer data showing toripalimab plus chemotherapy cut death risk 34%, together with regular China approval in urothelial cancer, failed to hold the stock up. Fundamentals are split: Q3 revenue rose 37.21% YoY to HK$956 million and operating profit jumped 230.21% to HK$172 million, yet the net loss was HK$200 million at a -20.9% margin versus a HK$49 million profit in Q2; PE stands at -33.41 and PB at 2.26. The shares are down 32.9% YTD, 51.46% below the 52-week high of HK$30.8 and only about 1% above the HK$14.8 low, trading under MA20 of HK$15.91 and MA60 of HK$17.29. While first patients have been dosed in the Phase 3 trials of JS207 plus JS007 in liver cancer and JS203 in lymphoma.
- Oct, 22
Junshi Biosciences opened at HK$17.05, slid to an intraday low of HK$16.33 and closed at HK$16.73, down 2.73% from the prior close of HK$17.20, as an earlier peer rights issue kept Hong Kong small-cap biotech sentiment under pressure and left individual names diverging. The move contrasts with Q2 numbers: revenue of HK$1.12bn, up 53.1% yoy, and net profit of HK$48.77m, up 125.03%, with EPS turning positive at HK$0.0429 versus -HK$0.0227 in Q1 and a 4.35% net margin, though Q2 operating profit stayed negative at -HK$58.78m. The stock trades below its MA20 of HK$17.60 and MA60 of HK$18.14, is down 24.91% year-to-date, sits 45.68% below the 52-week high of HK$30.80 and 9.7% above the HK$15.25 low. BNP Paribas earlier added 204,800 shares at HK$17.96, above the current price, while full-day volume reached about 1.79m shares on a 0.69% turnover rate.
- Oct, 21
Junshi Bio rose 3.74% to HK$17.20, opening flat at the prior close before grinding higher to an intraday peak of HK$17.45 at 11:35 BJ and easing back in the afternoon, on 1.877 million shares worth HK$32.3 million. The push came from the H1 turnaround: first-half revenue up 45% to RMB1.7 billion with net profit swinging to RMB25.5 million, while Q2 alone showed revenue of HK$1.12 billion (+53.1% yoy), net profit of HK$48.8 million (+125%) and EPS of HK$0.0429, alongside a partnership with Meijie Medical on multimodal drug-device combinations in oncology that earlier lifted the shares over 4% in one session. BNP Paribas added 204,800 shares at HK$17.96. Still, the price sits below its MA20 of 17.734 and MA60 of 18.178, 44.16% under the 52-week high of HK$30.80, with YTD down 22.8%, leaving a visible gap between improving fundamentals and price position.
- Oct, 7
Junshi Biosciences spiked early then faded, sliding about 3.5% to HK$17.89 from HK$18.54 after touching an intraday low of HK$17.22 at 09:51 BJ and recovering from HK$17.69 in the afternoon, on roughly HK$9.8 million turnover and a 0.21% turnover rate. Interim net profit of RMB25.5 million on revenue of RMB1.7 billion, up 45% year on year, together with UBS noting most China biotech firms beat 1H26 sales expectations, drove the morning pop; a key A-share investor's disclosed stake-reduction plan and the termination of the 2026 A-share employee ownership scheme capped the rebound. Q2 revenue of HK$1.119 billion rose 53.15% and net profit of HK$48.7 million rose 125.04%, yet the price sits below MA20 of 17.982 and MA60 of 18.526, down 19.7% year to date and about 45% below the 52-week high of 32.62. While profitability has only just turned positive on a thin base, the intraday range reached roughly 7%.
News
PUBT · Shanghai Junshi Biosciences Files HKEX Next-Day Return Disclosing Share Buyback for Cancellation
Market Movers · Junshi Bio falls 5%
Weekly Review · Weekly Recap | JUNSHI BIO +1.95%, consensus target above spot
Tip Ranks · Shanghai Junshi Biosciences Co., Ltd. Class H (1877) Gets a Buy from CICC
Market Movers · Junshi Bio hits 52-week low in Hong Kong trading
